Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RARG | P13631 | 11/20 | 1.00 |
| ▸ | RXRB | P28702 | 8/20 | 1.00 |
| ▸ | RXRG | P48443 | 8/20 | 1.00 |
| ▸ | RARA | P10276 | 7/20 | 1.00 |
| ▸ | RARB | P10826 | 7/20 | 1.00 |
| ▸ | PPARG | P37231 | 10/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175957 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL502043 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL502045 | 1.00 | RXRA (1.00) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8899800 | 0.94 | RXRA (0.88) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL13752421 | 0.89 | RXRA (0.81) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8568634 | 0.89 | RXRA (0.80) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL8568632 | 0.89 | RXRA (0.80) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL20646225 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6344906 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6344909 | 0.87 | RXRA (0.77) | RXRARARGRXRBRXRGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20090291492-A1 | METHOD FOR FORMING ORGAN | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-11-26 | — | — | US | claimed |
| US-20090016991-A1 | Rxr Antagonist Treatment Against Multiple Sclerosis | BOLLAG WERNER | 2009-01-15 | — | — | US | claimed |
| US-20080242729-A1 | Rxr Antagonists in the Treatment of Inflammatory Diseases | BOLLAG WERNER | 2008-10-02 | — | — | US | claimed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | claimed |
| EP-1771163-A1 | RXR ANTAGONIST TREATMENT AGAINST MULTIPLE SCLEROSIS | Bollag, Werner (CH) | 2007-04-11 | — | — | EP | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| WO-2006010504-A1 | RXR ANTAGONIST TREATMENT AGAINST MULTIPLE SCLEROSIS | BOLLAG WERNER (CH) | 2006-02-02 | — | — | WO | claimed |
| EP-1621191-A1 | Treatment of inflammatory diseases by RXR Antagonists | Bollag, Werner (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | claimed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| CN-114096313-A | P16 for use in the prevention or treatment of Huntington's diseaseINK4aInhibitors | 索邦大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20180320139-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL INC. | 2018-11-08 | — | — | US | disclosed |
| US-20160097037-A1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD. | 2016-04-07 | — | — | US | disclosed |
| EP-2206773-B1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD (IL) | 2012-07-11 | — | — | EP | disclosed |
| US-8105833-B2 | Method for forming organ | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-01-31 | — | — | US | disclosed |
| EP-2305794-A1 | Expansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2011-04-06 | — | — | EP | disclosed |
| US-20110033427-A1 | Expansion Of Renewable Stem Cell Populations | GAMIDA CELL LTD. (IL) | 2011-02-10 | — | — | US | disclosed |
| EP-2206773-A1 | Espansion of renewable stem cell populations | Gamida Cell Ltd. (IL) | 2010-07-14 | — | — | EP | disclosed |
| EP-1576089-B1 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2010-04-14 | — | — | EP | disclosed |
| US-20090291492-A1 | METHOD FOR FORMING ORGAN | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1799812-A4 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | GAMIDA CELL LTD (IL) | 2009-09-09 | — | — | EP | disclosed |
| EP-1648397-A4 | EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED ORGANS | GAMIDA CELL LTD (IL) | 2008-05-21 | — | — | EP | disclosed |
| EP-1649007-A4 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | GAMIDA CELL LTD (IL) | 2008-05-14 | — | — | EP | disclosed |
| US-20070161105-A1 | Method of forming organ | REASEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-07-12 | — | — | US | disclosed |
| EP-1799812-A2 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | Gamida Cell Ltd. (IL) | 2007-06-27 | — | — | EP | disclosed |
| US-20070082397-A1 | Ex vivo progenitor and stem cell expansion for use in the treatment of disease of endodermally-derived organs | GAMIDA-CELL LTD. (IL) | 2007-04-12 | — | — | US | disclosed |
| US-20070077652-A1 | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells | GAMIDA CELL LTD. | 2007-04-05 | — | — | US | disclosed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | disclosed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | disclosed |
| US-20060205071-A1 | Methods for ex-vivo expanding stem/progenitor cells | GAMIDA-CELL LTD. (IL) | 2006-09-14 | — | — | US | disclosed |
| EP-1648397-A2 | EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED ORGANS | Gamida Cell Ltd. (IL) | 2006-04-26 | — | — | EP | disclosed |
| EP-1649007-A2 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | Gamida Cell Ltd. (IL) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006030442-A2 | METHODS OF EX VIVO PROGENITOR AND STEM CELL EXPANSION BY CO-CULTURE WITH MESENCHYMAL CELLS | GAMIDA-CELL LTD. (IL) | 2006-03-23 | — | — | WO | disclosed |
| EP-1621191-A1 | Treatment of inflammatory diseases by RXR Antagonists | Bollag, Werner (CH) | 2006-02-01 | — | — | EP | disclosed |
| EP-1612264-A1 | ORGAN-FORMING METHOD | Research Foundation Itsuu Laboratory (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20050220774-A1 | Methods of inducing differentiation in ex vivo expanded stem cells | GAMIDA CELL LTD. (IL) | 2005-10-06 | — | — | US | disclosed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | disclosed |
| EP-1534820-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | Gamida Cell Ltd. (IL) | 2005-06-01 | — | — | EP | disclosed |
| US-20050054097-A1 | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures | GAMIDA CELL LTD. (IL) | 2005-03-10 | — | — | US | disclosed |
| WO-2005007073-A2 | EX VIVO PROGENITOR AND STEM CELL EXPANSION FOR USE IN THE TREATMENT OF DISEASE OF ENDODERMALLY-DERIVED ORGANS | GAMIDA-CELL LTD. (IL) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007799-A2 | METHODS FOR EX-VIVO EXPANDING STEM/PROGENITOR CELLS | GAMIDA-CELL LTD. (IL) | 2005-01-27 | — | — | WO | disclosed |
| US-20050008624-A1 | Expansion of renewable stem cell populations | GAMIDA CELL LTD. | 2005-01-13 | — | — | US | disclosed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | disclosed |
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | LIGAND PHARMACEUTICALS INC | 2004-03-11 | — | — | US | disclosed |
| WO-2004016731-A2 | EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL POPULATIONS IN MONONUCLEAR CELL CULTURES | GAMIDA-CELL LTD. (IL) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | disclosed |
| US-6593493-B1 | 2-(Carboxy(unsaturated)alkyl)-1-(haloalkoxy)benzene derivatives; retinoid X receptors; cardiovascular, skin, eating and vision disorders; anticarcinogenic agents; non-insulin-dependent diabetes | LIGAND PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| WO-2002013812-A1 | METHODS FOR TREATING INFLAMMATORY DISEASES | PERSHADSINGH HARRIHAR A (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20020019344-A1 | Methods of preventing allograft rejection | PERSHADSINGH HARRIHAR A (US) | 2002-02-14 | — | — | US | disclosed |
| US-20020019344-A1 | Methods of preventing allograft rejection | PERSHADSINGH HARRIHAR A (US) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016991-A1 | Rxr Antagonist Treatment Against Multiple Sclerosis | RXRA, RXRB, RXRG | RXRA 1/4885RARG 8/4885RXRB 2/4885 |
| US-20080242729-A1 | Rxr Antagonists in the Treatment of Inflammatory Diseases | RXRA, RXRB, RXRG | RXRA 1/4885RARG 6/4885RXRB 2/4885 |
| US-20040049072-A1 | RXR modulators with improved pharmacologic profile | RXRB, RXRG, RXRA | RXRA 3/4885RARG 20/4885RXRB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.